
Please try another search
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Name | Age | Since | Title |
---|---|---|---|
Ignacio Faus | - | 2023 | Deputy Managing Director & Director |
Bruno Lafont | - | 2006 | Founder, CEO, MD & Chairman |
Stuart G. Ferguson | - | - | Scientific Advisor |
Scott E. Lukas | - | - | Member of Scientific Advisory Board |
Dominique Cote | - | 2023 | Independent Board Member |
Eric Tartour | - | - | Member of Scientific Advisory Board |
Bernard Le Foll | - | 2025 | Member of Scientific Advisory Board |
Francis Ahner | - | 2024 | Director |
Yannick Pletan | 72 | 2024 | Chief Medical Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review